Fagron accelerates global expansion with two strategic acquisitions and a key North American licensing milestone

Core Insights - Fagron is expanding its global presence through two strategic acquisitions: Amber Compounding Pharmacy in Singapore and Malaysia, and Vepakum in Brazil, enhancing its capabilities in the pharmaceutical compounding market [1][2] - The acquisitions are expected to generate approximately €26 million in annual revenue with an EBITDA margin exceeding the current group margin, at a total purchase price of around €55 million, resulting in an average EV to EBITDA multiple of about 8x [3] - Fagron has also secured a license for its Anazao Health facility in Tampa, allowing the shipment of compounded medications to California, which strengthens its position in the U.S. healthcare market [4][7] Acquisition Details - Amber Compounding Pharmacy operates five strategic locations in Singapore and Malaysia, recognized as a leader in the compounding market, serving clinics, hospital pharmacies, and distributors [5] - Vepakum, based in São Paulo, Brazil, provides high-quality packaging solutions, enabling Fagron to achieve scale benefits through joint packaging and distribution [6] Licensing and Operational Updates - The license obtained for the Tampa facility allows for the shipment of compounded medications on a prescription basis, marking a significant milestone in Fagron's nationwide platform for Health and Wellness services [7][8] - Following the licensing, all Fagron facilities in the U.S. can now ship compounded medications to California, significantly enhancing operational flexibility [9]